Cyclized Peptide Complex for Leishmania Vaccine Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine candidates for visceral leishmaniasis face challenges in achieving effective protection and safety in natural hosts, such as dogs and humans, and struggle to distinguish between vaccinated and infected individuals, especially in endemic zones where symptoms are non-specific and diagnosis is uncertain.
Innovation Solution
A synthetic peptide complex comprising a cyclized 34-amino acid peptide (E34P) and two other non-native peptides (A16E and A16G) combined with an adjuvant, specifically inducing a Th1-type immune response and producing IgG2 antibodies, which can differentiate vaccinated from infected individuals and provide protection against Leishmania.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccine candidates (live, dead, or attenuated promastigotes) are used, then immunoprotection may be achieved in experimental models, but safety and effectiveness in natural hosts (dogs and humans) cannot be guaranteed
Solution Approach 1:
The patent extracts specific protective antigenic determinants from the complex promastigote structure and synthesizes them as discrete peptides (E34P, A16E, A16G). This extraction allows isolation of the protective components while eliminating harmful elements present in whole promastigotes, resolving the contradiction between effectiveness and safety in natural hosts.
Solution Approach 2:
The patent creates synthetic peptide copies of the essential protective antigens found in natural promastigotes. These synthetic copies (particularly the cyclized E34P peptide) replicate the protective function without the safety risks of live or dead promastigotes, enabling reliable immunoprotection in dogs and humans while maintaining safety.
2Reliability
If traditional vaccines are used, then some level of protection is achieved, but the ability to distinguish vaccinated from infected individuals is lost due to non-specific symptoms in endemic zones
Solution Approach 1:
The patent applies local quality by designing peptides with specific structural features (cyclization of E34P, specific amino acid sequences) that elicit a distinctive IgG2 antibody response. This localized structural optimization creates a specific immunological signature that can be detected and used to differentiate vaccinated from infected individuals, maintaining protection while enabling precise diagnostic differentiation.
3Reliability
If complex vaccine formulations are used to achieve effective protection, then immunoprotection is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent employs synthetic peptides that can be produced through straightforward chemical synthesis rather than complex biological systems. The cyclized E34P peptide and accompanying peptides (A16E, A16G) represent simplified, cost-effective vaccine components that maintain protective effectiveness while dramatically reducing manufacturing complexity and cost compared to traditional promastigote-based vaccines.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide complex effectively induces a Th1-type immune response, producing specific IgG2 antibodies that neutralize Leishmania proliferation, offering protection and enabling accurate differentiation between vaccinated and infected individuals, while being stable, affordable, and suitable for use in poor countries.
Implementation Method 1
a cyclized 34-amino acid peptide (E34P) and two other non-native peptides (A16E and A16G) combined with an adjuvant, specifically inducing a Th1-type immune response and producing IgG2 antibodies
Data Source
AI summary
Non-native synthetic peptide cyclized by means of a disulphide bridge, characterized by the amino acid sequence (E34P) that follows (SEQ ID No.1): E-D-E-H-K-G-K-Y-C-R-L-G-N-D-C-R-T-T-E-P-T-T-T-A-T-P-R-G-T-P-T-P-A-P and complex of non-native synthetic peptides that is intended to induce and characterize the prevention and/or treatment of conditions in mammals, the protective immunity of which depends on the stimulation of Th1 lymphocytes, and in particular a delayed hyperstimulation state, containing: - said peptide (E34P), - the following sequence (A16E) of 16 amino acids (SEQ ID No.2) or derivatives (structural analogues) thereof: A-A-R-C-A-R-C-R-E-G-Y-S-L-T-D-E - the following sequence (A16G) of 16 amino acids (SEQ ID No.3) or derivatives (structural analogues) thereof: A-A-S-S-T-P-S-P-G-S-G-C-E-V-D-G -, and an adjuvant which preferably induces a cell-mediated response.